Four patients with severe burn injuries received enoxaparin 40 mg twice/day subcutaneously for the prophylaxis of venous thromboembolism (VTE). Peak antifactor Xa levels were measured 4 hours after administration of a dose, and trough antifactor Xa levels were measured 30 minutes before the next scheduled dose. Ultrasonography was performed once/week to assess the presence of VTE. Any occurrence of major bleeding was documented in the patients' charts. All patients had trough antifactor Xa levels below 0.1 U/ml. Enoxaparin dosages were subsequently adjusted to achieve trough antifactor Xa levels of 0.1-0.2 U/ml. This required dosages higher than those typically recommended for VTE prophylaxis (40 mg every 24 hrs or 30 mg every 12 hrs). One patient needed more than 60 mg every 12 hours. No patient had a venous thromboembolic event or major bleeding. The low antifactor Xa levels that were observed suggest that a reduced dose-response relationship may exist between subcutaneously administered enoxaparin and antifactor Xa activity in patients with severe burn injuries. Prospective studies should be performed to further investigate this relationship.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1592/phco.24.17.1793.52344 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Concordance and discordance of anticoagulation assays in children supported by ECMO: The truth is out there.
Perfusion
December 2024
Department of Pediatrics, Section of Pediatric Critical Care Medicine, Yale, New Haven, CT, USA.
Introduction: Extracorporeal membrane oxygenation (ECMO) provides critical support to patients in severe cardiac and respiratory failure, but it requires anticoagulation to prevent complications like bleeding and thrombosis. Heparin, the primary anticoagulant utilized, is monitored by activated partial thromboplastin time (aPTT) and anti-Factor Xa (AntiXa) levels. Discordance between the two assays complicates its titration and the impact on patient outcomes is not well-established.
View Article and Find Full Text PDFBalancing safety and efficacy of low-molecular-weight heparins in neonates: a systematic review.
Res Pract Thromb Haemost
October 2024
Department of Pediatrics-Hematology, Emma Children's Hospital, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands.
The rising incidence of venous thromboembolism (VTE) in neonates has led to increased use of low-molecular-weight heparins (LMWHs), but optimal dosages remain uncertain. A serious adverse effect of LMWHs is major bleeding. Given the vulnerability of neonates to major bleeding, we aimed to review therapeutic and prophylactic LMWH dosages to achieve target anti-factor Xa ranges of 0.
View Article and Find Full Text PDFPregnant Woman in Outcomes with Prosthetic Heart Valves.
J Cardiovasc Dev Dis
November 2024
Almazov National Medical Research Centre, St. Petersburg 197341, Russia.
Article Synopsis
- This study investigated thrombotic and hemorrhagic complications during pregnancy, delivery, and postpartum in women with prosthetic heart valves (PHV), covering 88 pregnancies from January 2011 to December 2022.
- Of the pregnancies, 79 resulted in live births, with higher miscarriage rates in the mechanical valve prosthesis (MVP) group compared to the biological valve prosthesis (BVP) group, alongside notable thrombotic complications predominantly in the MVP group.
- While effective anti-factor Xa activity control was noted to reduce thrombotic events, the study highlighted a concerning rate of postpartum hemorrhagic complications, suggesting a need for revising anticoagulant therapy protocols.
Chemokine CXCL13 facilitates anti-FVIII inhibitory antibody development in hemophilia A patients and murine models.
Int Immunopharmacol
December 2024
Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory of Hematology, Fujian Medical University Union Hospital, Fuzhou, Fujian, China; Medical Technology and Engineering College of Fujian Medical University, Fuzhou, Fujian, China; Key Laboratory of Clinical Laboratory Technology for Precision Medicine (Fujian Medical University), Fujian Province University, Fuzhou, China. Electronic address:
Article Synopsis
- The study investigates the formation of anti-factor VIII (FVIII) inhibitors in hemophilia A patients and the role of the chemokine CXCL13 in this process.
- It was found that CXCL13 levels were significantly elevated in hemophilia A patients with inhibitors compared to those without, suggesting a link between CXCL13 and inhibitor development.
- The research indicates that targeting CXCL13 could be a promising therapeutic strategy for managing FVIII inhibitors in hemophilia A patients.
Evaluating chemical venous thromboembolism prophylaxis in trauma patients at a single Australian center.
J Trauma Inj
September 2024
Intensive Care Unit, Canberra Hospital, Garran, ACT, Australia.
Purpose: Trauma patients are at an elevated risk of developing venous thromboembolism (VTE), with the subsequent mortality in patients requiring intensive care unit admission ranging from 25% to 38%. There remains significant variability in clinical practice related to VTE prophylaxis in trauma patients due to the frequent presence of contraindications impacting the timing and consistency of application. This study aimed to assess the effectiveness of the current practice of chemical VTE prophylaxis in trauma patients at a single Australian center.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!